ICECHIP Data Policy

• All investigators participating in ICECHIP agree to promptly submit their final Quality Controlled data to the NCAR/EOL Field Data Archive (FDA) (or to an archive as specified in the ICECHIP Data Management Plan) along with required dataset documentation at the latest within 12 months after the end of the field phase (by 30 June 2026) to facilitate inter-comparison of results, quality control checks and inter-calibrations, as well as an integrated interpretation of the combined dataset. Data will be RESTRICTED for a total of 12 months (until 30 June 2026) so that Principal Investigators (PIs) may have exclusive access to the ICECHIP data.
• During this restricted data access period, defined as the total of a 12 month period following the end of the ICECHIP Field Project Deployment, ICECHIP Principal Investigators (PIs) may have exclusive access to this data. This time period is designed to provide an opportunity to refine algorithms to reflect real-world observations and quality control the combined dataset as well as to provide the investigators ample time to publish their results. Data may be password protected upon the request of the data provider.
• All EOL platform and instrument data will follow the EOL Data Policy.
• All ICECHIP data in the FDA will be considered Public Domain at 12 months following the end of the ICECHIP Field Project Deployment (i.e., on 1 July 2026 and thereafter). A dataset within the ICECHIP archive can be opened to the public domain earlier at the discretion of the data provider for this particular dataset.   
• All data shall be promptly provided to other ICECHIP investigators upon request. All ICECHIP investigators will have equal access to all data. A list of ICECHIP investigators will be maintained by NCAR/EOL and will include the Principal Investigators (PIs) directly participating in the field experiment as well as collaborating scientists who have provided guidance in the planning and analysis of ICECHIP data. All instrument PIs will participate in ongoing discussions about IOP selection and data priorities and will follow group decisions to the best of their capability.

• Authorship:

  During the restricted data access period, the investigator(s) who collected the data must be notified first of the intent to use the data, in particular if data is to be provided to a third party (e.g., journal articles, presentations, research proposals, other investigators).  Data users must follow the guidelines shown in the Authorship Guidelines for Peer-Reviewed Manuscripts Involving ICECHIP Data document.  Any use of the data should include an acknowledgment (i.e., citation).   In all circumstances, the PIs responsible for acquisition of data should be acknowledged appropriately. 

• International agencies, professional societies, and research organizations are moving towards requiring researchers to formally cite data and sources that led to a given research result. To support this, DOIs or Digital Object Identifiers (considered “perpetual” identifiers) will be assigned to FINAL datasets housed within the NCAR/EOL FDA. These DOIs should be used in ICECHIP related publications. DOIs will not be created for preliminary data.